Ignite Creation Date:
2025-12-25 @ 4:57 AM
Ignite Modification Date:
2025-12-26 @ 3:57 AM
Study NCT ID:
NCT06728618
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-12-11
First Post:
2024-12-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-03
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-08
First Submit QC Date:
None
Study First Post Date:
2024-12-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-08
Last Update Post Date:
2024-12-11
Last Update Post Date Type:
ACTUAL